2022 World Conference on Lung Cancer (ePosters)-EP08.01-001. Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer

EP08.01-001. Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer

Back to course

Pdf Summary

This document provides an update analysis of the combination therapy of Sintilimab with two cycles of chemotherapy for untreated advanced squamous non-small-cell lung cancer (sq-NSCLC). The study aimed to enhance the effectiveness of the treatment while minimizing toxicity.<br /><br />The clinical trial involved treatment-naïve sq-NSCLC patients who received Sintilimab with nab-paclitaxel and carboplatin for two cycles. Patients who did not experience disease progression continued to receive Sintilimab until progression, intolerable toxicity, death, or up to 2 years.<br /><br />The efficacy results showed that the median progression-free survival (PFS) was 8.5 months, with an 18-month PFS rate of 31.0%. The median overall survival (OS) was 17.7 months, with an 18-month OS rate of 46.8%. The objective response rate (ORR) was 73.9%, and the disease control rate (DCR) was 93.5%. The median time to response was 1.5 months, and the median duration of response (DOR) was not reached.<br /><br />In terms of safety, 95.7% of patients experienced treatment-related adverse events (TRAEs). Two patients (4.5%) had Grade 5 TRAEs, and eight patients (17.4%) experienced immune-related adverse events (irAEs).<br /><br />The document concludes that the combination therapy of Sintilimab with nab-paclitaxel/carboplatin demonstrated promising PFS and OS results and had a manageable safety profile as a first-line treatment for advanced sq-NSCLC.<br /><br />The baseline characteristics of the 46 enrolled and treated patients were also provided, including age, sex, smoking status, ECOG score, histology, and TNM stage.<br /><br />Overall, this study suggests that the combination therapy of Sintilimab with two cycles of chemotherapy may be a viable treatment option for untreated advanced sq-NSCLC patients.

Asset Subtitle

Huijuan Wang

Meta Tag

Speaker Huijuan Wang

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

combination therapy

Sintilimab

chemotherapy

untreated advanced squamous non-small-cell lung cancer

sq-NSCLC

clinical trial

progression-free survival

overall survival

adverse events

first-line treatment